Abstract:Background: Threats by enforced Intellectual Property (IP) rights to equitable HIV treatment access by poor populations are impending. India and China's policy directions in the field will be crucial in ultimately affecting the affordability and accessibility of antiretroviral (ARV) therapy in the under-served markets. These directions, together with the exploitation level of IP-bound flexibilities and the evolutionary modelling in partnerships and trade agreements between research-based and generic pharmaceutical industry, will also affect the outcomes of self-sufficiency efforts now at their beginning in the developing world as far as domestic manufacturing of generic ARV drugs is concerned. Aims: This paper explores key issues, implications and interaction dynamics across these challenging scenarios while attempting to provide equitable solution glimpses into the near future. Results: Access-oriented long-term drug policy strategies entitled to pass muster of governments, research-based as well as generic industries in both developed and developing countries are needed if equitable access to affordable ARV treatments by poor people has to be achieved despite enforced IP rights. Predictable dynamics between western multinationals and transitional country generic corporations let regard IP-bound Voluntary License flexibilities as a fitting measure into just mentioned needs especially if substantial incentives to generic corporations are concurrently secured. Efforts to equitably expand ARV drug access through exploiting IP opportunities should encompass attainment of self-sufficiency in domestic drug manufacturing whenever basic requirements are in place in the developing world as a whole. A credible industrial potential would act, indeed, as a boosting factor for drawing branded drug producers into technology transfer agreements, the terms of which would let all contractors enjoy substantial advantages. These perspectives consistently bind up with the foreseeable long-term trade and drug policy directions of India and China according to frontier crossing implications of their key IP management trends as well as their multifaceted penetration strategies of both the wealthy and under-served markets worldwide. As coherent with these perspectives, more disbursement by wealthy country governments and donors to basic infrastructure development in sub-Saharan African nations with stable governments in place is urged both as a priority for improving Africa's economy and a prerequisite for allowing domestic industrial plants to take off. Aiming at the targets just underscored, WHO's brokering role in negotiated agreements between wealthy and developing country-based firms as well as its technical guidance in setting international standards have always to be sought if equitable and appropriate end results are to be attained. Conclusion: Overall insights in this paper would mean that, while research-based corporations are to be praised whenever waiving, on humanitarian purposes, part of their profits, the trade and profit rules cannot basically be given up if long-term sustainable results are the goal to look for. Only negotiated agreements securing all contracting parties lasting advantages may ensure shifting of such a goal from mere vision to a really sustainable attainment.

Comments on Development for the Parallel Import of Patent Drugs

Pharmaceutical Patents in Developing Nations: Parallel Importation and the Doctrine of Exhaustion

A Discussion on Drug Accessibility and Drug Patent Protection

On Accessibility and Patent Protection of Drugs

Influences of parallel imports policy of patented goods on social welfare and China's countermeasures

Parallel imports and price controls

Affordable antiretroviral drugs for the under-served markets: how to expand equitable access against the backdrop of challenging scenarios?

On the Parallel Imports in Intellectual Property

Parallel imports, price controls, and innovation

The Implementation Status and Improvement Suggestions of Drug Patent Compulsory Licensing in China-Based on the COVID-19 Pandemic

Analysis of Medicine-related Issues in New "patent Law"

Analysis on the importance of drug patent system for new drug research and development from the particularity of drug

TRIPS and the Primacy of Public Health

Reconsideration on parallel imports of intellectual property rights licensing and legislative revelation to China

Impact of Parallel Trade on Pharmaceutical Firm’s Profits: Rise or Fall?

Drug Patent Monopoly During Covid-19 Outbreaks: How the Government Regulates this?

Drug innovation, price controls, and parallel trade

Technology Development Through Pooling ARV Drug Patents: A Vision from China.

Legal Protection against Patent and Intellectual Property Rights Violations Amidst COVID-19

EVALUATION OF PATENT PROTECTION IN PANDEMIC VACCINES AND DRUGS

Prior Consents: Preventing Offensive Genetic Engineering Patents Against Indigenous People's Rights